The failure of clinical trials to treat primary progressive MS with the PDE4 inhibitor rolipram suggests that other PDE families, such as PDE8, expressed in Teff cells might be important for controlling their pro-inflammatory function. Here, ALDH7A1 is linked to myeloid sarcoma.